Paolo Tarantino· @PTarantinoMD · X·· 21 hours agoScore70
Body
Very promising randomized results with the CDK4 selective inhibitor atirmociclib presented by @antgiorda. Next gen CDKs are here! #ESMO26 #ESMOAmbassadors
129 views · 0 likes · 1 repost · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.org🔹CDK4 selective inh Atirmociclib + fulvestrant improved mPFS vs investigator’s choice post-CDK4/6i in the FourLight-1 ph2 trial 🔹Neutropenia the most frequent AE & 1 related pneumontis death 🔹Next step: the FourLight-3 ph3 study in the 1L vs CDK4/6i #ESMO26 #ESMOAmbassadors在 X 查看被引用的帖子
Source: Paolo Tarantino · x.com